Understanding and preventing type 1 diabetes through the unique working model of TrialNet

Manuela Battaglia, Mark S. Anderson, Jane H. Buckner, Susan M. Geyer, Peter A. Gottlieb, Thomas W.H. Kay, Åke Lernmark, Sarah Muller, Alberto Pugliese, Bart O. Roep, Carla J. Greenbaum, Mark Peakman

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Type 1 diabetes is an autoimmune disease arising from the destruction of pancreatic insulin-producing beta cells. The disease represents a continuum, progressing sequentially at variable rates through identifiable stages prior to the onset of symptoms, through diagnosis and into the critical periods that follow, culminating in a variable depth of beta cell depletion. The ability to identify the very earliest of these presymptomatic stages has provided a setting in which prevention strategies can be trialled, as well as furnishing an unprecedented opportunity to study disease evolution, including intrinsic and extrinsic initiators and drivers. This niche opportunity is occupied by Type 1 Diabetes TrialNet, an international consortium of clinical trial centres that leads the field in intervention and prevention studies, accompanied by deep longitudinal bio-sampling. In this review, we focus on discoveries arising from this unique bioresource, comprising more than 70,000 samples, and outline the processes and science that have led to new biomarkers and mechanistic insights, as well as identifying new challenges and opportunities. We conclude that via integration of clinical trials and mechanistic studies, drawing in clinicians and scientists and developing partnership with industry, TrialNet embodies an enviable and unique working model for understanding a disease that to date has no cure and for designing new therapeutic approaches.

Original languageEnglish (US)
Pages (from-to)2139-2147
Number of pages9
JournalDiabetologia
Volume60
Issue number11
DOIs
StatePublished - Nov 1 2017

Fingerprint

Type 1 Diabetes Mellitus
Clinical Trials
Autoimmune Diseases
Industry
Biomarkers
Insulin
Therapeutics

Keywords

  • Autoimmunity
  • Mechanistic studies
  • Review
  • Type 1 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Battaglia, M., Anderson, M. S., Buckner, J. H., Geyer, S. M., Gottlieb, P. A., Kay, T. W. H., ... Peakman, M. (2017). Understanding and preventing type 1 diabetes through the unique working model of TrialNet. Diabetologia, 60(11), 2139-2147. https://doi.org/10.1007/s00125-017-4384-2

Understanding and preventing type 1 diabetes through the unique working model of TrialNet. / Battaglia, Manuela; Anderson, Mark S.; Buckner, Jane H.; Geyer, Susan M.; Gottlieb, Peter A.; Kay, Thomas W.H.; Lernmark, Åke; Muller, Sarah; Pugliese, Alberto; Roep, Bart O.; Greenbaum, Carla J.; Peakman, Mark.

In: Diabetologia, Vol. 60, No. 11, 01.11.2017, p. 2139-2147.

Research output: Contribution to journalReview article

Battaglia, M, Anderson, MS, Buckner, JH, Geyer, SM, Gottlieb, PA, Kay, TWH, Lernmark, Å, Muller, S, Pugliese, A, Roep, BO, Greenbaum, CJ & Peakman, M 2017, 'Understanding and preventing type 1 diabetes through the unique working model of TrialNet', Diabetologia, vol. 60, no. 11, pp. 2139-2147. https://doi.org/10.1007/s00125-017-4384-2
Battaglia M, Anderson MS, Buckner JH, Geyer SM, Gottlieb PA, Kay TWH et al. Understanding and preventing type 1 diabetes through the unique working model of TrialNet. Diabetologia. 2017 Nov 1;60(11):2139-2147. https://doi.org/10.1007/s00125-017-4384-2
Battaglia, Manuela ; Anderson, Mark S. ; Buckner, Jane H. ; Geyer, Susan M. ; Gottlieb, Peter A. ; Kay, Thomas W.H. ; Lernmark, Åke ; Muller, Sarah ; Pugliese, Alberto ; Roep, Bart O. ; Greenbaum, Carla J. ; Peakman, Mark. / Understanding and preventing type 1 diabetes through the unique working model of TrialNet. In: Diabetologia. 2017 ; Vol. 60, No. 11. pp. 2139-2147.
@article{eef5a1ea6564425181febc2a437ffd33,
title = "Understanding and preventing type 1 diabetes through the unique working model of TrialNet",
abstract = "Type 1 diabetes is an autoimmune disease arising from the destruction of pancreatic insulin-producing beta cells. The disease represents a continuum, progressing sequentially at variable rates through identifiable stages prior to the onset of symptoms, through diagnosis and into the critical periods that follow, culminating in a variable depth of beta cell depletion. The ability to identify the very earliest of these presymptomatic stages has provided a setting in which prevention strategies can be trialled, as well as furnishing an unprecedented opportunity to study disease evolution, including intrinsic and extrinsic initiators and drivers. This niche opportunity is occupied by Type 1 Diabetes TrialNet, an international consortium of clinical trial centres that leads the field in intervention and prevention studies, accompanied by deep longitudinal bio-sampling. In this review, we focus on discoveries arising from this unique bioresource, comprising more than 70,000 samples, and outline the processes and science that have led to new biomarkers and mechanistic insights, as well as identifying new challenges and opportunities. We conclude that via integration of clinical trials and mechanistic studies, drawing in clinicians and scientists and developing partnership with industry, TrialNet embodies an enviable and unique working model for understanding a disease that to date has no cure and for designing new therapeutic approaches.",
keywords = "Autoimmunity, Mechanistic studies, Review, Type 1 diabetes",
author = "Manuela Battaglia and Anderson, {Mark S.} and Buckner, {Jane H.} and Geyer, {Susan M.} and Gottlieb, {Peter A.} and Kay, {Thomas W.H.} and {\AA}ke Lernmark and Sarah Muller and Alberto Pugliese and Roep, {Bart O.} and Greenbaum, {Carla J.} and Mark Peakman",
year = "2017",
month = "11",
day = "1",
doi = "10.1007/s00125-017-4384-2",
language = "English (US)",
volume = "60",
pages = "2139--2147",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Understanding and preventing type 1 diabetes through the unique working model of TrialNet

AU - Battaglia, Manuela

AU - Anderson, Mark S.

AU - Buckner, Jane H.

AU - Geyer, Susan M.

AU - Gottlieb, Peter A.

AU - Kay, Thomas W.H.

AU - Lernmark, Åke

AU - Muller, Sarah

AU - Pugliese, Alberto

AU - Roep, Bart O.

AU - Greenbaum, Carla J.

AU - Peakman, Mark

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Type 1 diabetes is an autoimmune disease arising from the destruction of pancreatic insulin-producing beta cells. The disease represents a continuum, progressing sequentially at variable rates through identifiable stages prior to the onset of symptoms, through diagnosis and into the critical periods that follow, culminating in a variable depth of beta cell depletion. The ability to identify the very earliest of these presymptomatic stages has provided a setting in which prevention strategies can be trialled, as well as furnishing an unprecedented opportunity to study disease evolution, including intrinsic and extrinsic initiators and drivers. This niche opportunity is occupied by Type 1 Diabetes TrialNet, an international consortium of clinical trial centres that leads the field in intervention and prevention studies, accompanied by deep longitudinal bio-sampling. In this review, we focus on discoveries arising from this unique bioresource, comprising more than 70,000 samples, and outline the processes and science that have led to new biomarkers and mechanistic insights, as well as identifying new challenges and opportunities. We conclude that via integration of clinical trials and mechanistic studies, drawing in clinicians and scientists and developing partnership with industry, TrialNet embodies an enviable and unique working model for understanding a disease that to date has no cure and for designing new therapeutic approaches.

AB - Type 1 diabetes is an autoimmune disease arising from the destruction of pancreatic insulin-producing beta cells. The disease represents a continuum, progressing sequentially at variable rates through identifiable stages prior to the onset of symptoms, through diagnosis and into the critical periods that follow, culminating in a variable depth of beta cell depletion. The ability to identify the very earliest of these presymptomatic stages has provided a setting in which prevention strategies can be trialled, as well as furnishing an unprecedented opportunity to study disease evolution, including intrinsic and extrinsic initiators and drivers. This niche opportunity is occupied by Type 1 Diabetes TrialNet, an international consortium of clinical trial centres that leads the field in intervention and prevention studies, accompanied by deep longitudinal bio-sampling. In this review, we focus on discoveries arising from this unique bioresource, comprising more than 70,000 samples, and outline the processes and science that have led to new biomarkers and mechanistic insights, as well as identifying new challenges and opportunities. We conclude that via integration of clinical trials and mechanistic studies, drawing in clinicians and scientists and developing partnership with industry, TrialNet embodies an enviable and unique working model for understanding a disease that to date has no cure and for designing new therapeutic approaches.

KW - Autoimmunity

KW - Mechanistic studies

KW - Review

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85026746218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026746218&partnerID=8YFLogxK

U2 - 10.1007/s00125-017-4384-2

DO - 10.1007/s00125-017-4384-2

M3 - Review article

C2 - 28770323

AN - SCOPUS:85026746218

VL - 60

SP - 2139

EP - 2147

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 11

ER -